KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Long-Term Debt Repayments (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Long-Term Debt Repayments for 14 consecutive years, with $501.0 million as the latest value for Q3 2025.

  • Quarterly Long-Term Debt Repayments rose 24950.0% to $501.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Sep 2025, up 2.73% year-over-year, with the annual reading at $48.0 million for FY2021, 96.4% down from the prior year.
  • Long-Term Debt Repayments hit $501.0 million in Q3 2025 for Abbott Laboratories, up from $1.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q3 2023 to a low of $1.0 million in Q2 2022.
  • Historically, Long-Term Debt Repayments has averaged $269.4 million across 5 years, with a median of $3.0 million in 2021.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 144400.0% in 2023 and later crashed 99.86% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $3.0 million in 2021, then plummeted by 66.67% to $1.0 million in 2022, then skyrocketed by 144400.0% to $1.4 billion in 2023, then plummeted by 99.86% to $2.0 million in 2024, then soared by 24950.0% to $501.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for ABT at $501.0 million in Q3 2025, $1.0 million in Q2 2025, and $1.0 billion in Q1 2025.